                         SEQUENCE LISTING

<110>  Apogenix GmbH
 
<120>  Method of predicting the responsiveness of a cancer disease to 
       treatment on the basis of DNA methylation

<130>  57195P EP

<140>  EP14151345.7
<141>  2014-01-15

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  400
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Recombinant fusion protein consisting of human CD95 extracellular
       domain with human IgG1 FC-part to its C-terminus


<220>
<221>  SIGNAL
<222>  (1)..(16)
<223>  Variable cleavage sites

<220>
<221>  SIGNAL
<222>  (1)..(20)
<223>  Variable cleavage sites

<220>
<221>  SIGNAL
<222>  (1)..(25)
<223>  Variable cleavage sites

<220>
<221>  DOMAIN
<222>  (26)..(172)
<223>  Human CD95 extracellular domain

<220>
<221>  MOD_RES
<222>  (26)..(26)
<223>  PYRROLIDONE CARBOXYLIC ACID

<220>
<221>  DISULFID
<222>  (59)..(73)

<220>
<221>  DISULFID
<222>  (63)..(82)

<220>
<221>  DISULFID
<222>  (85)..(101)

<220>
<221>  DISULFID
<222>  (104)..(119)

<220>
<221>  DISULFID
<222>  (107)..(127)

<220>
<221>  CARBOHYD
<222>  (118)..(118)
<223>  N-linked Glycosylation at Position N118

<220>
<221>  DISULFID
<222>  (129)..(143)

<220>
<221>  DISULFID
<222>  (135)..(140)

<220>
<221>  CARBOHYD
<222>  (136)..(136)
<223>  N-linked Glycosylation at Position N136

<220>
<221>  DISULFID
<222>  (146)..(157)

<220>
<221>  DISULFID
<222>  (149)..(165)

<220>
<221>  DOMAIN
<222>  (172)..(400)
<223>  Human IgG1-FC domain (one amino acid overlap with CD95 domain)

<220>
<221>  DISULFID
<222>  (173)..(173)
<223>  Interchain cystine forming residue.

<220>
<221>  DISULFID
<222>  (179)..(179)
<223>  Interchain cystine forming residue.

<220>
<221>  DISULFID
<222>  (182)..(182)
<223>  Interchain cystine forming residue

<220>
<221>  DISULFID
<222>  (214)..(274)

<220>
<221>  CARBOHYD
<222>  (250)..(250)
<223>  N-linked Glycosylation at Position N250

<220>
<221>  DISULFID
<222>  (320)..(378)

<400>  1

Met Val Gly Ile Trp Thr Leu Leu Pro Leu Val Leu Thr Ser Val Ala 
1               5                   10                  15      


Arg Leu Ser Ser Lys Ser Val Asn Ala Gln Val Thr Asp Ile Asn Ser 
            20                  25                  30          


Lys Gly Leu Glu Leu Arg Lys Thr Val Thr Thr Val Glu Thr Gln Asn 
        35                  40                  45              


Leu Glu Gly Leu His His Asp Gly Gln Phe Cys His Lys Pro Cys Pro 
    50                  55                  60                  


Pro Gly Glu Arg Lys Ala Arg Asp Cys Thr Val Asn Gly Asp Glu Pro 
65                  70                  75                  80  


Asp Cys Val Pro Cys Gln Glu Gly Lys Glu Tyr Thr Asp Lys Ala His 
                85                  90                  95      


Phe Ser Ser Lys Cys Arg Arg Cys Arg Leu Cys Asp Glu Gly His Gly 
            100                 105                 110         


Leu Glu Val Glu Ile Asn Cys Thr Arg Thr Gln Asn Thr Lys Cys Arg 
        115                 120                 125             


Cys Lys Pro Asn Phe Phe Cys Asn Ser Thr Val Cys Glu His Cys Asp 
    130                 135                 140                 


Pro Cys Thr Lys Cys Glu His Gly Ile Ile Lys Glu Cys Thr Leu Thr 
145                 150                 155                 160 


Ser Asn Thr Lys Cys Lys Glu Glu Gly Ser Arg Ser Cys Asp Lys Thr 
                165                 170                 175     


His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 
            180                 185                 190         


Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 
        195                 200                 205             


Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 
    210                 215                 220                 


Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 
225                 230                 235                 240 


Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 
                245                 250                 255     


Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 
            260                 265                 270         


Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 
        275                 280                 285             


Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 
    290                 295                 300                 


Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 
305                 310                 315                 320 


Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 
                325                 330                 335     


Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 
            340                 345                 350         


Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 
        355                 360                 365             


Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 
    370                 375                 380                 


Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
385                 390                 395                 400 


<210>  2
<211>  375
<212>  DNA
<213>  Homo sapiens


<220>
<221>  primer_bind
<222>  (75)..(99)

<220>
<221>  misc_feature
<222>  (135)..(136)
<223>  cg06983746

<220>
<221>  misc_feature
<222>  (180)..(181)
<223>  cg10161121

<220>
<221>  primer_bind
<222>  (224)..(246)

<400>  2
ttaagggaaa tatttttgtt tttttttttt tttatttttt tttttttgat tttgtttttt       60

aaagaaatat ttatttattt tgtagttgaa gttgagaagt tttaagaagt ttagagtaaa      120

tttttggaag ttttcgttta taattttttg ataatagttt ttaaggtttt agttgttgtc      180

gttgtgttat ttaaataggt tagtaggtta tgtttatttt tttgggattt tgtagagtag      240

gttagtatgg gggtatagtt ttgttagtgt gaattgtttt tagttatagg agaatggtta      300

gtggggttat aattttatga attataattg tatgtttttt tatatattat aattgtataa      360

ttttaagaat tttat                                                       375


<210>  3
<211>  35
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Forward primer


<220>
<221>  misc_feature
<222>  (1)..(35)
<223>  forward primer

<400>  3
aggaagagag ttattttgta gttgaagttg agaag                                  35


<210>  4
<211>  54
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Reverse primer


<220>
<221>  misc_feature
<222>  (1)..(54)
<223>  reverse primer

<400>  4
cagtaatacg actcactata gggagaaggc tactaaccta ctctacaaaa tccc             54


